• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Obstetrics

Nivolumab may be effective in platinum-resistant ovarian cancer

byMonica ParksandDavid Wang
September 20, 2015
in Obstetrics, Oncology
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

1. In a phase II clinical trial of 20 patients with platinum-resistant ovarian cancer, the use of nivolumab, a monoclonal antibody against programmed-death 1 (PD-1) receptor, demonstrated positive efficacy and tolerability.

Evidence Rating Level: 2 (Good)

Study Rundown: Due to its frequent diagnosis at advanced stages, ovarian cancer carries the highest mortality among all gynecologic malignancies. Previous reports have demonstrated that activation of the programmed cell PD-1 receptors in T-cells suppress cancer immune reactions and has been shown to be a negative prognostic factor in ovarian cancer. Nivolumab, an anti-PD-1 receptor monoclonal antibody, may interfere with this pathway and improve the cancer immune response. The purpose of this phase II clinical trial was to evaluate the safety and antitumor effect of this novel agent in ovarian cancer patients.

The study recruited 20 women with platinum-resistant ovarian cancer and followed their clinical response to nivolumab at two different doses (1mg/kg or 3mg/kg) for a median duration of 11 months. At the conclusion of this small clinical trial, the best overall response rate was 15% with a disease control rate of 45%. In terms of safety, grade 3 and 4 adverse reactions occurred in 40% of patients; however, the majority of patients (19 of 20) were able to complete the treatment course. The patient cohort on the higher dose of nivolumab demonstrated higher efficacy without an increase in frequency of adverse events. The results of this phase II trial are encouraging and support the implementation of larger phase III trials to further assess the efficacy of nivolumab in platinum-resistant ovarian cancer.

Click to read the study in JCO

Relevant Reading: Tumor cell expression of programmed cell death-1 ligand is a prognostic factor for malignant melanoma

RELATED REPORTS

Nivolumab plus ipilimumab improves survival over lenvatinib or sorafenib in liver cancer

Nivolumab plus ipilimumab improves progression-free survival in metastatic colorectal cancer

Neoadjuvant ipilimumab plus nivolumab improves event-free survival in stage III melanoma

In-Depth [randomized controlled trial]: This was a single-center, open-label, phase II clinical trial that enrolled 20 women with platinum-resistant advanced ovarian cancer that has failed previous platinum or taxane-based therapies. Patients were excluded if they had a previous history of anti-PD-1 antibody therapy or evidence of chronic immunosuppression. Overall, 20 patients were recruited and assigned sequentially to a low-dose cohort (1mg/kg) followed by the high-dose cohort (3mg/kg). The primary outcome was the best overall response (RR) as assessed by RECIST (Response Evaluation Criteria In Solid Tumors). Secondary end points were drug safety, adverse events, progression-free survival (PFS), overall survival (OS), and disease control rate. At the conclusion of the trial, the overall RR was 15% (95% CI: 3.2% to 37.9%) and the disease control rate was 45% (95% CI: 23.1% to 68.5%). Median PFS and OS were 3.5 months and 20 months, respectively. Grade 3 to 4 adverse events occurred in 40% of patients; however, 19 out of 20 patients completed treatment. There was no difference in adverse reaction rate between the low-dose versus high-dose cohort. The most common adverse events were transaminitis, thyroiditis, lymphocytopenia, fever, rash, arthralgia, arrhythmia, and fatigue.

Image: PD

©2015 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: Nivolumabovarian cancer
Previous Post

Late gestation antidepressant use linked to postpartum hemorrhage

Next Post

Nurses working extended shifts report greater burnout and job dissatisfaction

RelatedReports

Prognostic indicators for transarterial chemoembolization in patients with hepatocellular carcinoma with extrahepatic spread identified
AI Roundup

Nivolumab plus ipilimumab improves survival over lenvatinib or sorafenib in liver cancer

June 12, 2025
Development of a risk index for colorectal cancer screening
Chronic Disease

Nivolumab plus ipilimumab improves progression-free survival in metastatic colorectal cancer

April 3, 2025
Increased risk of subsequent melanoma after first melanoma diagnosis
Dermatology

Neoadjuvant ipilimumab plus nivolumab improves event-free survival in stage III melanoma

December 12, 2024
Radiographic surrogates may predict tumor-specific survival in renal carcinoma
Chronic Disease

Nivolumab does not improve survival in patients with advanced renal cell carcinoma with progression after immune checkpoint inhibitors

October 30, 2024
Next Post
Nurses working extended shifts report greater burnout and job dissatisfaction

Nurses working extended shifts report greater burnout and job dissatisfaction

Fruit consumption among US youth differs by age, race

Fruit consumption among US youth differs by age, race

E-interventions linked to short-term reduction in alcohol consumption in college students

Alcohol abuse linked to teens’ early maturation, minimal supervision

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Sodium-glucose cotransporter 2 inhibitors may decrease risk of serious liver events in patients with cirrhosis
  • #VisualAbstract: Lactated Ringer’s Solution Does Not Improve Outcomes Relative to Normal Saline
  • 2MM: AI Roundup – FDA’s AI Push, Trial Speedups with Real-World Data, Smart Surgical Monitors, and Regulatory Overhaul Begins [July 2nd, 2025]
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
No Result
View All Result

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.